After December 2018, we will be moving
elements from the doctorportal newsletter to MJA InSight
newsletter and rebranding it to Insight+. If you’d like to
continue to receive a newsletter covering the latest on research
and perspectives in the medical industry, please subscribe to the Insight+
newsletter here.

As of January 2019, we will no longer be
sending out the doctorportal email newsletter. The final issue
of this newsletter will be distributed on 13 December 2018.
Articles from this issue will be available to view online until
31 December 2018.

[Series] Clinical management of psoriatic arthritis

June 12, 2018

The Lancet 391, 10136 (2018)

Author: Filip Van den Bosch, Laura Coates

Psoriatic arthritis, or the broader term psoriatic disease, refers to an inflammatory disorder that affects multiple organs, including the skin and joints, and that also has related extra-articular manifestations and can have comorbidities. Patients with psoriatic disease have a substantial clinical burden. Early identification leading to timely diagnosis and treatment is crucial to prevent long-term structural damage and disability and the associated socioeconomic consequences. The increase in therapeutic options, such as disease-modifying anti-rheumatic drugs, both biological and targeted synthetic, has revolutionised the treatment of skin and joint disease, and has prompted clinicians to use the full clinical picture of an individual patient to make rational treatment decisions.